Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease

Diabetes, Obesity and Metabolism

Volumn 4, Issue SUPPL. 2, 2002, Pages

  Belch, Jill J F ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Intermittent claudication; Peripheral arterial disease; Risk factors

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ARTERY DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HEMODYNAMICS; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIFESTYLE; LIMB AMPUTATION; MORTALITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; FEMALE; HYPERLIPIDEMIA; INCIDENCE; MALE; METABOLISM; MORBIDITY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; RISK;

FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; MALE; MORBIDITY; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; SMOKING;

EID: 0344890251     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2002.0040s20s7.x     Document Type: Review

References (52)

1. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982; 211: 249-256.
2. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J 1986; 293: 1137-1140.
3. Criqui MH, Fronek A, Barrett-Connor E et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-515.
4. Fowkes FGR, Housley E, Cawood EH, Macintyre CG, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
5. Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis 1981; 34: 261-269.
6. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥ 62 years of age. Am J Cardiol 1994; 74: 64-65.
7. Vogt MT, Cauley JA, Newman AE, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-469.
8. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993; 270: 487-489.
9. Dormandy JA. Natural history of intermittent claudication. Hospital Update 1991; 17: 314-320.
10. Bloor K. Natural history of arteriosclerosis of the lower extremities. Ann R Coll Surg Engl 1961; 28: 36-51.
11. Second European Consensus Document on chronic critical leg ischemia. Eur J Vasc Surg 1992; 6 (Suppl. A): 1-32.
12. Dormandy JA, Rutherford RB, for the TASC Working Group et al. Management of peripheral arterial disease. J Vasc Surg 2000; 31: S1-S296.
13. Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol 1992; 45: 529-542.
14. Liedberg E, Persson BM. Age, diabetes and smoking in lower limb amputation for arterial occlusive disease. Acta Orthop Scand 1983; 54: 383-388.
15. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997; 96: 44-49.
16. Khan F, Elhadd TA, Greene SA, Belch JJF. Impaired skin microvascular function in children, adolescents and young adults with Type-1 (insulin-dependent) diabetes mellitus. Diabetes Care 2000; 23: 215-219.
17. Farkouh ME, Rihal CS, Gersh BJ et al. Influence of coronary heart disease on morbidity and mortality after lower extremity revascularization surgery: a population-based study in Olmsted County, Minnesota (1970-87). J Am Coll Cardiol 1994; 24: 1290-1296.
18. Criqui MH, Browner D, Fronek A et al. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease: an analysis of risk factors. Am J Epidemiol 1989; 129: 1110-1119.
19. Da Silva A, Widmer LK, Ziegler HW, Nissen C, Schweiger W. The Basle longitudinal study; report on the relation of initial glucose level to baseline ECG abnormalities, peripheral arterial disease, and subsequent mortality. J Chron Dis 1979; 32: 797-803.
20. Beach KW, Bedford GR, Bergelin RO et al. Progression of lower-extremity arterial occlusive disease in type II diabetes mellitus. Diabetes Care 1988; 11: 464-472.
21. Kreines K, Johnson E, Albrink M et al. The course of peripheral vascular disease in non-insulin dependent diabetics. Diabetes Care 1985; 8: 235-242.
22. Janka HV, Standl E, Mehnert H. Peripheral vascular disease in diabetes mellitus and its relation to cardiovascular risk factors. Diabetes Care 1980; 3: 207-213.
23. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs: the Framingham study. JAMA 1972; 221: 661-666.
24. Elhadd TA, Robb R, Jung RT, Stonebridge PA, Belch JJF. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Pract Diabetes Int 1999; 16: 163-166.
25. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J 1978; 1: 1379-1381.
26. Kannel WB, Shurtleff D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics 1973; 28: 61-68.
27. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg 1996; 11: 402-408.
28. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication: incidence in the Framingham Study. Circulation 1970; 41: 875-883.
29. Zimmerman BR, Palumbo PJ, O'Fallon WM, Ellefson RD, Osmundson PJ, Kazmier FJ. A prospective study of peripheral occlusive arterial disease in diabetes III. initial lipid and lipoprotein findings. Mayo Clinic Proc 1981; 56: 233-242.
30. Duffield RGM, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis: a randomised controlled trial. Lancet 1983; ii: 639-642.
31. The Lipid Research Clinics Coronary Primary Prevention Trial results I. reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
32. Caldwell S, McCarthy M, Martin SC et al. Hyperhomocysteinaemia, peripheral vascular disease and neointimal hyperplasia in elderly patients. Br J Surg 1998; 85: 685-715.
33. Boushey CJ, Beresford SAA, Omenn GS et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.
34. Robinson K, Mayer E, Jacobsen DW. Homocysteine and coronary artery disease. Cleve Clin J Med 1994; 61: 438-450.
35. Belch JJF, Mackay IR, Hill A, Jennings P, McCollum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol 1996; 14: 385-388.
36. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992; 73: 346-353.
37. Carmargo CA, Stampfer MJ, Glynn RJ et al. Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation 1997; 95: 577-580.
38. Housley E, Leng GC, Donnan PT, Fowkes FGR. Physical activity and risk of peripheral arterial disease in the general population. Edinburgh Artery Study. J Epidemiol Commun Health 1993; 47: 475-180.
39. Westendorp ICD, in't Veld BA, Grobbee DE et al. Hormone replacement therapy and peripheral arterial disease. The Rotterdam Study. Arch Intern Med 2000; 160: 2498-2502.
40. Manson JE, Hu FB, Rich-Edwards JW et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341: 650-658.
41. Sesso HD, Paffenbarger RS Jr, Lee I-M. Physical activity and coronary heart disease in men. The Harvard Alumni Health Study. Circulation 2000; 102: 975-980.
42. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 1984; 56: 831-838.
43. Ali A, Mandeep MR, Lavie CJ et al. Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and 'normal' lipid levels. Am J Cardiol 1998; 82: 1543-1545.
44. Hulley S, Grady D, Bush T et al. for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
45. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149-153.
46. Kennedy G, McLaren M, Belch JJF, Seed M. Elevated levels of sE-selectin in post-menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females. Thromb Haemost 2000; 82: 1433-1436.
47. Mosca L. The role of hormone replacement therapy in prevention of postmenopausal heart disease. Arch Intern Med 2000; 160: 2263-2272.
48. Radack K, Deck C. Beta adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomised controlled trials. Arch Intern Med 1991; 151: 1769-1776.
49. Khan F, Litchfield SJ, Stonebridge PA, Belch JJF. Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease. Vasc Med 1999; 4: 233-238.
50. Hittel N, Donnelly R. Treating peripheral arterial disease in patients with diabetes. Diab Obes Metab 2002; 4 (Suppl. 2): 26-31.
51. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296 320-331.
52. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.